StreetAlpha.app
Home › Stocks › ALLO

Allogene Therapeutics, Inc. (ALLO)

Healthcare
$0.63
▼ −5.88%
LAST CLOSE · NOV 20

Allogene Therapeutics develops engineered T cell treatments from healthy donor cells for cancer and autoimmune diseases. It last closed at $0.63 on Nov 20, down 5.88% on the day. The next earnings report for ALLO is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, ALLO reported EPS of -$0.15 on revenue of $0. Over its last 8 reports the stock moved an average of 6.7% the session after earnings. Over the last 12 months ALLO insiders bought $0 of stock on the open market and sold $668K, according to SEC Form 4 filings.

AI Auto Pilots
Is ALLO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ALLO.

Key Stats

Last 12 months
Results
Revenue
$4.6M
Net income
−$174.5M
−3760.0% margin
EPS (diluted)
−$0.61
Free cash flow
−$108.8M
−2345.0% margin
Valuation
Market cap
$217.5M
346.5M shares
P/E
–
No P/E while losing money
Price to sales
46.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.3M
At Sep 30
Shareholder equity
$392.6M
Shares outstanding
346.5M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $114.1M$114.1MFY2021FY2022: $156K$156KFY2022FY2023: $95K$95KFY2023FY2024: $22K$22KFY2024FY2025: $0$0FY2025

From ALLO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$0.15
Quarter ended Sep 2026
Year ago EPS
-$0.19
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.28Dec '24Mar 2025: -$0.28Mar '25Jun 2025: -$0.23Jun '25Sep 2025: -$0.19Sep '25Dec 2025: -$0.17Dec '25Mar 2026: -$0.18Mar '26Jun 2026: -$0.13Jun '26Sep 2026: -$0.15Sep '26Latest -$0.15
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Jun 2026: $4.6MJun '26Sep 2026: $0Sep '26Latest $0
How ALLO moved after its last 8 reports
Average move the session after a report ±6.7%
Nov 5, 2026After the close−4.6%
Aug 12, 2026After the close−4.3%
May 13, 2026After the close−8.2%
Mar 12, 2026After the close−2.8%
Nov 6, 2025After the close+12.4%
Aug 13, 2025After the close+2.9%
May 13, 2025After the close−15.7%
Mar 13, 2025After the close+2.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ALLOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ALLO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ALLO

Technical Analysis

ALLO · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 58% below its 20 day and 107% below its 50 day average. It is 206% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 17), oversold. The nearest support is the 52 week low at $0.62, and the nearest resistance the Pivot at $0.64.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.1%/day
Key levels
$4.4652 week high+607.9%
$1.92200 day average+204.8%
$1.63100 day average+158.7%
$1.36Swing high (Oct 21)+115.9%
$1.3050 day average+106.3%
$0.9920 day average+57.1%
$0.66Pivot R1+4.8%
$0.64Pivot+1.6%
$0.63Last close
$0.6252 week low−1.6%
$0.61Pivot S1−3.2%
Indicators
RSI (14)17.04Oversold below 30Oversold
MACD-0.19Below its signal lineBearish
Stochastic2.0Near the bottom of its rangeOversold
ADX (14)52.8Strong downtrend
Williams %R-98.5Oversold below −80, overbought above −20Oversold
CCI (20)-131.1Oversold below −100, overbought above 100Oversold
Rate of change−39.6%Change over 10 sessionsBearish
ATR (14)$0.09Typical daily range, 14.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALLO

What happened before

See how ALLO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ALLO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ALLO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ALLOHow many large options trades hit ALLO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ALLO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼81 buying vs 108 selling
  • ▼Held by funds -2.5 pts
  • ▼Funds holding -11
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding198209−5.3%
In funds' top 10440.0%
Held by funds87.8%90.2%−2.5 pts
New / increased25 / 5632 / 99−38.2%
Reduced / sold out74 / 3451 / 30+33.3%
Put/call ratio0.080.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALLO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ALLO Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$668K14 sales · 6 insiders
2026-01 sold $41K2026-02 sold $337K2026-03 sold $156K2026-04 sold $22K2026-08 sold $63K2026-10 sold $49KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 21Geoffrey M. ParkerCFOSale36,342$1.34$49K
Aug 21Earl Martin DouglasSVP, General CounselSale29,697$2.12$63K
Apr 21Annie YoshiyamaSVP, FinanceSale9,586$2.31$22K
Mar 31Benjamin Machinas BeneskiSVP, Chief Technical OfficerSale2,867$2.50$7K
Mar 16David D ChangPresident and CEOSale47,763$2.47$118K
Mar 16Benjamin Machinas BeneskiSVP, Chief Technical OfficerSale4,835$2.47$12K
Every insider buy and sale for ALLO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ALLO insider trades →

From SEC Form 4 filings by ALLO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALLO is in one of them and how their past ALLO trades turned out.

ALLO in the AI portfolios
Loading…

ALLO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALLO in an article yet. Here's the latest on the wider market.

ALLO in the news

About Allogene Therapeutics

Allogene Therapeutics is a biotechnology company based in South San Francisco, California, that develops engineered T cell treatments for cancer and autoimmune diseases. Its treatments are made from healthy donor cells, so they can be prepared ahead of time and given to any eligible patient rather than made from each patient's own cells. Its main candidates target lymphoma, kidney cancer and autoimmune conditions such as lupus, and they are in clinical trials with patients as the intended users.

Headquarters
South San Francisco, CA